Search clinical trials for: recomon (Epoetin Beta)

Total 6536 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Anemia | Renal Diseases

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Treatment of Anemia in Diabetic Subjects With CKD

Anemia
Ortho Biotech Products, L.P.

Completed

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

HIV Infections | Anemia
Janssen-Cilag B.V.

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Cancer | Anemia | Neoplasm
Janssen-Ortho Inc., Canada

Completed

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Anemia | Kidney Failure | Left Ventricular Hypertrophy
John A Widness
National Heart, Lung, and Blood Institute (NHLBI); Janssen Scientific Affairs... and other collaborators

Completed

Optimized Erythropoietin (EPO) Treatment (OETNA)

Neonatal Anemia

United States
Ortho Biotech Products, L.P.

Terminated

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Cancer | Anemia | Chemotherapy
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Ortho Biotech Products, L.P.

Terminated

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Multiple Myeloma | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

Anemia | Kidney Failure, Chronic
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Quality of Life | Breast Neoplasms | Anemia
Ortho Biotech, Inc.

Completed

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Cancer | Anemia | Chemotherapy
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease (CKD)

United States, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
Charite University, Berlin, Germany

Completed

Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy (EPOHeart)

Ischemic Cardiomyopathy

Germany
Bio Sidus SA

Completed

Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers

Anemia
Federico II University
Friedreich's Ataxia Research Alliance; Associazione Italiana per la lotta alle...

Completed

Efficacy Study of Epoetin Alfa in Friedreich Ataxia (FRIEMAX)

Friedreich Ataxia

Italy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

The Duration Study

Anemia
University of New Mexico
National Center for Research Resources (NCRR)

Completed

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

Preterm Infants

United States
Sports Medicine Research and Testing Laboratory

Completed

CD71 in Dried Blood Spots in Healthy Males

Healthy Athletes

United States
Amgen

Completed

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

Renal Insufficiency, Chronic | Anemia | Renal Dialysis | Erythrocyte Transfusion

United States, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Anemia
University Medical Center Groningen
Radboud University Medical Center

Unknown

Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model (IPIIR)

Myocardial Infarction | Ischemia-Reperfusion Injury

Netherlands
Sundsvall Hospital

Completed

Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.

Multiple Myeloma | Anemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Sweden
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

Anemia

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene

Completed

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Myelodysplastic Syndromes

France, Monaco
AstraZeneca
FibroGen

Completed

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

Anemia

United States, Thailand, Vietnam, Canada, Peru, Philippines, Slovakia, Poland, Russian Federation, Ukraine, Czechia, Spain, Hungary, Australia, Bulgaria, India, Mexico, Sweden
Ortho Biotech Products, L.P.

Terminated

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Quality of Life | Breast Neoplasms | Anemia | Hemoglobins | Chemotherapy, Adjuvant
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Sandoz
Hexal AG

Completed

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. (EPO-PASS)

Chronic Kidney Disease

Poland, Germany, Romania, Italy, Austria, Bulgaria, France, Macedonia, The Former Yugoslav Republic of, Russian Federation, Ukraine
Penang Hospital, Malaysia

Unknown

Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'

End Stage Renal Failure | Anaemia
Sandoz

Completed

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) (SENSE)

Chronic Kidney Disease

Russian Federation, Germany, Italy, Poland, Romania, Turkey, Ukraine
Sandoz

Completed

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa (ACCESS)

Anemia | Chronic Kidney Disease (CKD)

United States
Amgen

Terminated

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Anemia

United States
Amgen

Completed

EPO Deep Tank in Dialysis Subjects

Chronic Kidney Disease
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Anemia

Italy, Spain, France, Canada, Hungary, United States, Germany, Belgium, Poland, Australia, Israel, United Kingdom, Czech Republic
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Australian and New Zealand Intensive Care Research...
Monash University; University College Dublin; Health Research Board, Ireland; Health... and other collaborators

Recruiting

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

Wounds and Injuries | Trauma | Traumatic Brain Injury | Multiple Trauma | Major Trauma | Traumatic Injury | Penetrating Injury | Blunt Injury

Australia, Ireland, Finland, New Zealand, Slovenia, Germany, Saudi Arabia, Switzerland
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Anaemia

Korea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada
University of Florida
Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

Anemia

United States
Hospital Son Espases

Recruiting

Paricalcitol Improves Anemia of Inflammation (PIERAID)

Anemia

Spain
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Lymphoma | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Region Skane

Completed

Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery (EPRICS)

Renal Failure | Kidney Failure

Sweden
Anemia Working Group Romania
Dr Carol Davila Teaching Hospital of Nephrology; Romanian Renal Registry

Withdrawn

Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules (VAES)

Bio-Equivalency of 2 Treatment Schedules in HD Patients

Romania

Search clinical trials for: recomon (Epoetin Beta)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations